31.51
4.75%
+1.43
Pacira BioSciences Inc Borsa (PCRX) Ultime notizie
National Bank of Canada FI Takes Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
MarketBeat
National Bank of Canada FI Purchases New Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Defense World
Moving Average Crossover Alert: Pacira BioSciences (PCRX) - Yahoo Singapore News
Yahoo Singapore News
Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
MarketBeat
Moving Average Crossover Alert: Pacira BioSciences (PCRX) - Yahoo Singapore News
Yahoo Singapore News
Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase ... - br.ADVFN.com
br.ADVFN.com
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of “Buy” from Analysts - Defense World
Defense World
Pacira (PCRX) Misses Q2 Earnings and Revenue Estimates - Yahoo Movies UK
Yahoo Movies UK
Pacira BioSciences (NASDAQ:PCRX) Sees Strong Trading Volume - Defense World
Defense World
Pacira BioSciences (NASDAQ:PCRX) Price Target Lowered to $43.00 at Needham & Company LLC - Defense World
Defense World
Pacira announces $250 million convertible notes offering - Investing.com India
Investing.com India
Pacira (PCRX) Lags Q1 Earnings Estimates - Yahoo Canada Shine On
Yahoo Canada Shine On
Earnings Preview: Pacira (PCRX) Q1 Earnings Expected to Decline - Yahoo Canada Shine On
Yahoo Canada Shine On
Pacira (PCRX) Lags Q3 Earnings Estimates - Yahoo Singapore News
Yahoo Singapore News
Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models - Simply Wall St
Simply Wall St
Earnings Miss: Pacira BioSciences, Inc. Missed EPS By 17% And Analysts Are Revising Their Forecasts - Yahoo Finance UK
Yahoo Finance UK
Pacira (PCRX) Q4 Earnings and Revenues Beat Estimates - Yahoo Canada Shine On
Yahoo Canada Shine On
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible ... - GlobeNewswire
GlobeNewswire
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible ... - Yahoo Finance
Yahoo Finance
Pacira BioSciences' (PCRX) Buy Rating Reaffirmed at HC Wainwright - Defense World
Defense World
Pacira BioSciences (NASDAQ:PCRX) Sees Unusually-High Trading Volume - MarketBeat
MarketBeat
Pacira BioSciences (NASDAQ:PCRX) Given Buy Rating at HC Wainwright - MarketBeat
MarketBeat
Pacira BioSciences (NASDAQ:PCRX) PT Lowered to $38.00 - MarketBeat
MarketBeat
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible ... - GlobeNewswire
GlobeNewswire
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
GlobeNewswire Inc.
Analyst Ratings For Pacira BioSciences - Pacira BioSciences (NASDAQ:PCRX) - Benzinga
Benzinga
Pacira BioSciences up 12% on stock buyback, Q1 top-line beat - Seeking Alpha
Seeking Alpha
Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues - Yahoo Finance Australia
Yahoo Finance Australia
Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues - Zacks Investment Research
Zacks Investment Research
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2024 Earnings Call Transcript - Insider Monkey
Insider Monkey
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2024 Earnings Call Transcript - Insider Monkey
Insider Monkey
Pacira reports solid Q1 earnings, announces $150 million buyback - Investing.com India
Investing.com India
Earnings call: Pacira BioSciences maintains positive outlook in Q1 2024 - Investing.com Australia
Investing.com Australia
Pacira reports solid Q1 earnings, announces $150 million buyback - Investing.com Canada
Investing.com Canada
Pacira reports solid Q1 earnings, announces $150 million buyback - Investing.com
Investing.com
Earnings call: Pacira BioSciences maintains positive outlook in Q1 2024 - Investing.com India
Investing.com India
Russell Investments Group Ltd. Sells 123756 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Defense World
Earnings call: Pacira BioSciences maintains positive outlook in Q1 2024 - Investing.com UK
Investing.com UK
Pacira reports solid Q1 earnings, announces $150 million buyback - Investing.com Australia
Investing.com Australia
Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues - Zacks Investment Research
Zacks Investment Research
Pacira BioSciences Inc (PCRX) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth and Robust Sales ... - GuruFocus.com
GuruFocus.com
Iceberg Image Closes Pacira Drug Patent Infringement Trial - Law360
Law360
Pacira BioSciences, Inc. 2024 Q1 - Results - Earnings Call Presentation (NASDAQ:PCRX) - Seeking Alpha
Seeking Alpha
Pacira BioSciences Reports Q1 2024 Results: Aligns with EPS Projections and Announces $150 ... - Yahoo Finance
Yahoo Finance
Here's What Key Metrics Tell Us About Pacira (PCRX) Q1 Earnings - Yahoo Finance
Yahoo Finance
Pacira reports solid Q1 earnings, announces $150 million buyback - Investing.com UK
Investing.com UK
Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase ... - wallstreet:online
wallstreet:online
Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program
GlobeNewswire Inc.
Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference - Yahoo Finance
Yahoo Finance
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Yousif Capital Management LLC - Defense World
Defense World
Capitalizzazione:
|
Volume (24 ore):